Biocon Limited (BIOCON) share price and analysis
BIOCON last traded at ₹359.40 (-0.77%) on the NSE. Market cap ₹58,861 Cr (Mid cap), Pharma & Healthcare sector.
Overall rating: 2.4/10 (Poor)
- Valuation: 2.9/10
- Profitability: 1.1/10
- Growth: 1.3/10
- Financial health: 5.0/10
- Price trend: 1.8/10
Long-term view: Avoid. Serious weaknesses in the business, the valuation or both. Trade bias (next few weeks): Strong short. Trend and momentum are clearly pointing down.
Strengths of BIOCON
- Debt / equity (0.42): Comfortable debt level.
- Analyst target (₹412 (+14.6%)): 19 analysts' average target implies +14.6%, moderate upside.
- Momentum (RSI 14) (RSI 50): Mildly positive momentum.
- Volatility (1Y) (26% annualised): Below-average volatility.
Weaknesses of BIOCON
- Valuation (P/E) (P/E 120.6 vs sector 41.1): Expensive at 2.9× the sector median P/E. High expectations are already priced in.
- Return on equity (1.0%): Very low or negative return on equity.
- Long-term trend (-7.8% vs 200-DMA): Well below its 200-day average, in a long-term downtrend.
- Profit growth (YoY) (-61.5%): Profits are falling sharply.
- 50-DMA vs 200-DMA (-6.3% gap): 50-day average is below the 200-day (death-cross setup), so medium-term momentum is down.
- 6-month performance vs Nifty 50 (-16.4% vs +7.4%): Badly underperforming the Nifty 50.
- Free cash flow (Negative): Burning cash, because free cash flow is negative. Growth is being funded by debt, equity or reserves.
- Net profit margin (2.6%): Low margins leave little room for cost shocks.
- Revenue growth (YoY) (+2.2%): Sales are shrinking slightly.
- 52-week range (20% below high): In the lower part of its 52-week range.
Key numbers
| Number | Value | Assessment | Normal range |
|---|---|---|---|
| P/E (TTM) | 120.6 | Expensive vs peers | 37.0–49.3 (sector median 41.1) |
| Forward P/E | 37.7 | Profits expected to grow | below today's P/E (120.6) and near 41 |
| Price / book | 1.70 | Low | 2–6 |
| EPS (TTM) | ₹2.98 | Profitable | above ₹0 |
| Return on equity | 1.0% | Weak | 15%+ (below 10% is weak) |
| Debt / equity | 0.42 | Low debt | below 1.0 (under 0.5 is great) |
| Net margin | 2.6% | Thin | 10%+ (below 5% is thin) |
| Operating margin | 9.1% | Thin | 20%+ strong, below 10% thin |
| Revenue growth | +2.2% | Shrinking | 10%+ a year (below 3% is weak) |
| Profit growth | -61.5% | Falling | 10%+ a year (falling is weak) |
| Dividend yield | 0.14% | Small payout | 1.5%+ (none is fine for growth firms) |
| Current ratio | 1.22 | Adequate | 1.5+ (below 1 is tight) |
| 52W high | ₹447.15 | 20% below · far from the high | price in the top 40% of its 52-week range |
| 52W low | ₹318.40 | Price is 13% above it | |
| 50-DMA | ₹365.56 | Price 1.7% below | price above it = short-term uptrend |
| 200-DMA | ₹389.98 | Price 7.8% below | price above it = long-term uptrend |
| 1Y return | -6.0% | Lagged the Nifty 50 | Nifty 50 did −0.4% |
| Beta | 0.34 | Steadier than the market | 0.8–1.3 (1 = moves with market) |
| Promoter / insider | 48.2% | Moderate stake | 50%+ shows owner commitment |
| Institutions | 33.4% | Strong big-investor interest | 30%+ is strong |
| Analyst target | ₹411.84 | 14.6% upside · 19 analysts | 8%+ upside |
Questions about BIOCON
What is the share price of Biocon Limited (BIOCON) today?
BIOCON last traded at ₹359.40 (-0.77% on the day) on the NSE. Its 52-week range is ₹318.40 to ₹447.15. Prices are delayed and come from Yahoo Finance.
Is BIOCON a good stock for the long term?
StockLens rates BIOCON 2.4 out of 10 (Poor) overall. Its long-term verdict is "Avoid": Serious weaknesses in the business, the valuation or both. Strengths: low debt, analyst upside, positive momentum. Concerns: expensive vs peers, weak ROE, downtrend.
Is BIOCON share overvalued?
BIOCON trades at a P/E of 120.6 against a Pharma & Healthcare median of 41.1, which StockLens rates as "Expensive vs peers". Its price-to-book ratio is 1.70.
Is BIOCON good for short-term trading?
The trade bias for the next few weeks is "Strong short": Trend and momentum are clearly pointing down. The price is 7.8% below its 200-day average and 14-day RSI is 50.
Which stocks are similar to BIOCON?
Similar Pharma & Healthcare stocks of comparable size include Alkem Laboratories, Glenmark Pharmaceuticals, Lupin, Max Healthcare, Aurobindo Pharma. You can compare up to 4 of them side by side on StockLens.
About Biocon Limited
Biocon Limited, together with its subsidiaries, manufactures biotechnology products and offers research services in India, the United States, Ireland, rest of the European Union, and internationally. It operates through Generics; Biosimilars; and Contract Research, Development and Manufacturing Organization (CRDMO) segments. The company offers generic formulations and API products, including cardiovascular, anti-diabetics, obesity, central nervous system, anti-cancer/oncology, multiple sclerosis, immunosuppressants, and specialty molecules; and biosimilars products for oncology, diabetes, and immunology therapeutic areas. It also provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal health, consumer goods, and specialty chemical industries, as well as academic institutions, non-profit organizations, and government agencies. In addition, the company offers enzyme, biopharmaceutical, and medicinal goods; contract research and manufacturing services; clinical research; and business support and development, and marketing services. Biocon Limited was incorporated in 1978 and is headquartered in Bengaluru, India.
Stocks similar to BIOCON
- Alkem Laboratories share price
- Glenmark Pharmaceuticals share price
- Lupin share price
- Max Healthcare share price
- Aurobindo Pharma share price
- Cipla share price
Compare BIOCON with ALKEM, GLENMARK, LUPIN
Educational information, not investment advice. Data from Yahoo Finance and NSE Indices; prices may be delayed.